学术研究-爱科百发

中文 EN

研发创新

专注于呼吸系统、儿科疾病
创新药物研发和商业化

Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection

Zhao S, et al. The New England Journal of Medicine. September 2024

查看详情→
Novel small-molecule inhibitors of SARS-CoV-2 main protease with nanomolar antiviral potency

Zhang H, et al. Journal of Infection. February 2024

查看详情→
Current state and challenges in respiratory syncytial virus drug discovery and development

Zou G, et al. Antiviral Research. Jan 2024

查看详情→
A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein

Dai L, et al. hLife. November 2023

查看详情→
Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: A phase 2 proof-of-concept trial

Huang LM, et al. Influenza Other Respi Viruses. July 2023

查看详情→
Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor

Zheng XF, et al. Journal of Medicinal Chemistry. July 2019

查看详情→
Comparison of antiviral resistance across acute and chronic viral infections

Mason S, et al. Antiviral Research. October 2018

查看详情→

电话：+86-21-50681677
地址：中国上海市浦东新区盛荣路388弄25号
邮箱：ir@arkbiosciences.com

爱科百发官方公众号

© 2021-2024 Ark Biopharmaceutical 沪ICP备2021015938号-1 沪公网安备 31011502017941

        
首页

电话

顶部